The notion that MAP4K4 may be a new target for the treatment of neurodegenerative diseases was already previously postulated in a study using optimized small molecule compounds based on the neuritogenic pyridones (militarinone-inspired 4-hydroxy-2-pyridone) collection (50). The gene discussed is MAP4K4; the disease is neurodegenerative disease.